Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EWTX
Upturn stock ratingUpturn stock rating

Edgewise Therapeutics Inc (EWTX)

Upturn stock ratingUpturn stock rating
$13.11
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: EWTX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

10 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $38.5

1 Year Target Price $38.5

Analysts Price Target For last 52 week
$38.5Target price
Low$10.6
Current$13.11
high$38.12

Analysis of Past Performance

Type Stock
Historic Profit 40.01%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.39B USD
Price to earnings Ratio -
1Y Target Price 38.5
Price to earnings Ratio -
1Y Target Price 38.5
Volume (30-day avg) 10
Beta 0.29
52 Weeks Range 10.60 - 38.12
Updated Date 06/30/2025
52 Weeks Range 10.60 - 38.12
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.55

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -21.08%
Return on Equity (TTM) -30.29%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 951553906
Price to Sales(TTM) -
Enterprise Value 951553906
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2.6
Shares Outstanding 105200000
Shares Floating 62576247
Shares Outstanding 105200000
Shares Floating 62576247
Percent Insiders 0.42
Percent Institutions 104.03

Analyst Ratings

Rating 4
Target Price 38.5
Buy 3
Strong Buy 5
Buy 3
Strong Buy 5
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Edgewise Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for severe, inherited muscle disorders. Founded to address unmet needs in Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD), Edgewise has advanced rapidly through preclinical and clinical development stages.

business area logo Core Business Areas

  • Muscle Disease Therapeutics: Focuses on the research, development, and commercialization of therapies for Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), and other inherited muscle disorders, targeting underlying causes rather than just symptom management.

leadership logo Leadership and Structure

The leadership team consists of experienced pharmaceutical executives and scientific advisors specializing in neuromuscular diseases. The organizational structure supports efficient preclinical and clinical development, with a strong emphasis on research and development.

Top Products and Market Share

overview logo Key Offerings

  • EDG-5506: EDG-5506 is an orally administered small molecule designed to address DMD and BMD. It inhibits myosin, thereby reducing muscle damage caused by excessive contraction and relaxation cycles. Currently in Phase 2/3 clinical trials. Market share is currently 0% as the product is not yet approved. Competitors include Sarepta Therapeutics (SRPT), PTC Therapeutics (PTCT), and Solid Biosciences (SLDB).

Market Dynamics

industry overview logo Industry Overview

The neuromuscular disease therapeutics market is experiencing substantial growth driven by advancements in gene therapy, small molecule drugs, and personalized medicine. High unmet medical needs and increasing awareness of rare diseases contribute to market expansion.

Positioning

Edgewise Therapeutics Inc. is positioned as an innovator in the muscle disease therapeutic space, particularly with its focus on small molecule myosin inhibitors. This approach offers a potential advantage over gene therapies and other modalities in terms of accessibility and scalability.

Total Addressable Market (TAM)

The DMD and BMD market is expected to reach billions of dollars annually. Edgewise is positioned to capture a significant share of this market with successful development and commercialization of EDG-5506. Estimated TAM is around $3 billion by 2030.

Upturn SWOT Analysis

Strengths

  • Novel Mechanism of Action (Myosin Inhibition)
  • Strong Intellectual Property Portfolio
  • Experienced Management Team
  • Clinical-Stage Asset with Promising Early Data

Weaknesses

  • Single Lead Product (EDG-5506)
  • High Cash Burn Rate typical of Biotech companies
  • Clinical Trial Risks and Regulatory Hurdles
  • Reliance on Successful Clinical Trial Outcomes

Opportunities

  • Expansion into Additional Muscle Disease Indications
  • Potential Partnerships and Collaborations
  • Orphan Drug Designation and Regulatory Benefits
  • Market Growth in Neuromuscular Disease Therapeutics

Threats

  • Competition from Established Pharmaceutical Companies
  • Clinical Trial Failures
  • Regulatory Delays or Rejection
  • Patent Infringement or Invalidity

Competitors and Market Share

competitor logo Key Competitors

  • SRPT
  • PTCT
  • SLDB
  • NSDQ

Competitive Landscape

Edgewise Therapeutics Inc. faces competition from companies with approved therapies and those developing gene therapies. Its small molecule approach offers a potential competitive advantage in terms of accessibility and scalability, but it must demonstrate superior efficacy and safety in clinical trials.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily reflected in increased research and development activities and stock appreciation/depreciation based on clinical trial progress.

Future Projections: Future growth depends on successful completion of clinical trials for EDG-5506 and potential expansion into other indications. Analyst estimates vary widely depending on clinical trial success probabilities.

Recent Initiatives: Recent initiatives include ongoing Phase 2/3 clinical trials for EDG-5506, presentations at scientific conferences, and strategic collaborations.

Summary

Edgewise Therapeutics Inc. is a promising clinical-stage company focused on developing therapies for muscle disorders, particularly DMD and BMD. The company's lead product, EDG-5506, has shown potential, but its success hinges on positive clinical trial results and regulatory approval. The company has a strong leadership team and novel MOA, but also faces competition and the high risk inherent in pharmaceutical development, but faces challenges of securing future funding as it is an early stage company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Edgewise Therapeutics Inc. website, SEC Filings, ClinicalTrials.gov, Analyst Reports

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Edgewise Therapeutics Inc

Exchange NASDAQ
Headquaters Boulder, CO, United States
IPO Launch date 2021-03-26
President, CEO & Director Dr. Kevin Koch Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 117
Full time employees 117

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.